View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 29, 2020updated 12 Jul 2022 11:34am

Regeneron’s antibody cocktail meets endpoints in Covid-19 trial

Regeneron Pharmaceuticals has reported positive results from an ongoing Phase II/III seamless trial of investigational antibody cocktail, REGN-COV2, in the Covid-19 outpatient setting. 

Regeneron Pharmaceuticals has reported positive results from an ongoing Phase II/III seamless trial of investigational antibody cocktail, REGN-COV2, in the Covid-19 outpatient setting.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Data from the trial showed that REGN-COV2 significantly reduced viral load and patient medical visits, including hospitalisations, emergency room, urgent care visits and/or physician office/telemedicine visits.

Designed to block infectivity of SARS-CoV-2, REGN-COV2 is a combination of two monoclonal antibodies REGN10933 and REGN10987.

The randomised, double-blind trial is analysing the effect of adding REGN-COV2 to usual standard-of-care as compared to placebo.

Last month, Regeneron reported data from the descriptive analysis of the trial of REGN-COV2 showing it reduced viral load and the time to alleviate symptoms in non-hospitalised patients with Covid-19.

The latest data, involving an additional 524 patients, showed that the trial met all the first nine endpoints.

No significant difference in virologic or clinical efficacy between the 8g and 2.4g dose of REGN-COV2 was reported.

Regeneron Pharmaceuticals president and chief scientific officer George Yancopoulos said: “Today’s analysis, involving more than 500 additional patients, prospectively confirms that REGN-COV2 can indeed significantly reduce viral load and further shows that these viral reductions are associated with a significant decrease in the need for further medical attention.”

On the primary endpoint, the average daily change in viral load by day seven in patients with high viral load was a 0.68 log10 copies/mL greater reduction with REGN-COV2 versus placebo.

In the overall patient group with detectable virus at baseline, the average daily reduction in viral load by day seven was a 0.36 log10 copies/mL reduction with the antibody cocktail compared to placebo.

Treatment with REGN-COV2 reduced Covid-19 related medical visits by 57% by day 29.

Regeneron shared the latest data with the US Food and Drug Administration (FDA), which is reviewing an emergency use authorisation (EUA) submission for the low dose of REGN-COV2 in high-risk patients with mild-to-moderate Covid-19.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena